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S U M M A R Y
Background: In 2013, the World Health Organization (WHO) recommended that for efﬁciency and ethical
considerations, transitioning from antenatal clinic-based surveillance to prevention of mother-to-child
transmission (PMTCT)-based routine data should be investigated. An assessment of the readiness for this
transition was carried out in Rwanda in 2011 and 2013.
Methods: This assessment applied the WHO recommended method. Individual HIV rapid testing at site
was compared to antenatal surveillance results at all existing 30 sites, involving 13 292 women. In
addition, PMTCT HIV testing quality assurance and PMTCT routine data quality were assessed at 27 out of
the 30 sites.
Results: All sentinel sites provided PMTCT services and had a high uptake of HIV testing (more than 90%).
At all sites, PMTCT data were recorded in longitudinal and standardized antenatal clinic registers.
Twenty-six out of 27 sites had HIV result completeness above 90%. A positive percentage agreement of
97.5% and negative percentage agreement of 99.9% were observed between routine PMTCT and sero-
surveillance HIV test results. Of 27 sites, 25 scored more than 80% in all phases of HIV testing quality
assurance.
Conclusions: According to WHO standards, Rwanda antenatal care HIV sero-surveillance is ready to
transition to PMTCT-based sero-surveillance.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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The last decade has seen remarkable changes in the global HIV
epidemic. An estimated 35.3 million people were living with HIV in
2012, an increase from previous years and mainly attributable to
people living longer due to successful antiretroviral therapy
programs.1 Simultaneously, the incidence of HIV has been falling,
with a 33% decline in the number of new infections from 2001
(3.4 million) to 2012 (2.3 million). The number of AIDS-related
deaths also declined from 2.3 million in 2005 to 1.6 million in
2012.1* Corresponding author.
E-mail address: bahelene@gmail.com (H. Balisanga).
http://dx.doi.org/10.1016/j.ijid.2016.08.029
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).HIV surveillance activities have been crucial to track the
progress of the epidemic, understand the burden of HIV disease,
and inform HIV control interventions. HIV sentinel surveillance
among pregnant women attending antenatal clinic sentinel sites
has been the cornerstone of HIV surveillance in countries with
generalized epidemics (deﬁned as HIV prevalence greater than 1% in
the general population).2 Historically, antenatal care HIV sero-
surveillance (ANC-HSS) has been conducted using the method of
unlinked anonymous testing (UAT). Introduced by the World Health
Organization (WHO) in 1988, UAT extracts routinely recorded
demographic information and collects remnant blood samples from
specimens provided for routine antenatal care (ANC) services from
antenatal clinic attendees. These data and specimens are then
permanently delinked from all personally identiﬁable information
and sent to a regional or central laboratory for HIV testing andciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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exploring the feasibility of shifting HIV surveillance to using
routinely collected prevention of mother-to-child transmission
(PMTCT) program data,3 for two primary reasons. First, there were
ethical concerns about the UAT approach, as women do not give
consent to participate or provide blood, nor do they receive the
surveillance HIV test results. Second, the use of routinely collected
data would demand less resources and be more sustainable than
ANC-HSS.3–8 In 2013, the WHO published guidelines to support
country assessments of their readiness to transition from ANC-HSS
to PMTCT-based sero-surveillance (PMTCT-SS).3
In Rwanda, the prevalence of HIV has stabilized at 3% in the
general population.9 The Rwanda Ministry of Health has used ANC-
HSS to track the HIV epidemic since 1998, expanding from six
initial sentinel sites to 24 sentinel sites in 2002 and to 30 sites in
2005. Rwanda used the UAT approach for ANC-HSS through 2007,
but transitioned to using linked anonymous testing (LAT) with
informed consent in 2011 in order to collect data to assess
readiness to switch from ANC-HSS to PMTCT-SS. Due to strong
integration of ANC and PMTCT services and data quality
improvement strategies, interest in the use of routine PMTCT
data for ANC-HSS increased. It is against this context that the
readiness for routine PMTCT data use was assessed. The assess-
ment examined the ﬁve key areas, the ﬁve key areas are: (i) uptake
of HIV testing in antenatal clinics, (ii) percent bias, (iii) the quality
of routinely collected PMTCT program data, (iv) the PMTCT HIV
rapid testing quality assurance parameters and (v) the accuracy of
PMTCT HIV testing results.
2. Methods
This study included all 30 sites in the 2011 Rwanda ANC-SS
round. Except for Kigali City, which is represented by three urban
sentinel sites, each of the remaining four provinces were
represented by at least two urban and two rural sites. Among
the 30 sites, 14 were located in urban areas and 16 in rural areas.
The assessment included three distinct data collection activities:
(1) the capture of routine PMTCT HIV testing information as part of
the 2011 ANC-SS at the 30 sites; (2) a PMTCT HIV testing quality
assurance assessment at 27 of the 30 sites; and (3) a retrospective
PMTCT data quality assessment at 27 of the 30 sites.
2.1. The capture of routine PMTCT HIV testing information as part of
the 2011 ANC-HSS
For the 2011 ANC-HSS, the survey population consisted of
pregnant women, aged 15–49 years, making their ﬁrst antenatal
visit (during their current pregnancy) at one of the 30 sentinel sites
during the surveillance period. Women were excluded from the
study if they were referred by another health facility or if they were
attending a follow-up ANC visit. According to standard ANC service
delivery, all women were offered routine HIV testing in the context
of PMTCT. Women who accepted HIV testing received a venous
blood draw and on-site HIV testing according to the national HIV
diagnostic algorithm: all blood specimens were screened by
Determine HIV-1/2 (Abbott Laboratories, Abbott Park, IL, USA) and
positive specimens were conﬁrmed by SD Bioline HIV-1/2 3.0
(Standard Diagnostics Inc., at, Hagal-Dong, Giheng-Ku, Yongin-Si,
Kyonggi-do Korea); the Uni-Gold HIV rapid test (Trinity Biotech,
Dublin, Ireland) was used as a tie-breaker. The results of rapid HIV
testing were provided to women on the same day.
Women who accepted HIV testing were also recruited for the
surveillance survey. Women providing informed consent were
administered a brief interview capturing basic demographic data
and PMTCT HIV testing uptake and results, and a remnant of their
routine blood sample provided for syphilis and other tests was sentwith the interview form to the National Reference Laboratory
(NRL) for HIV testing linked by a unique surveillance code. These
samples were tested by ELISA using HIV Vironostika HIV Uni-Form
II Ag/Ab (bioMe´rieux, Marcy l’Etoile, France) fourth-generation as
the screening test and Murex HIV Ag/Ab Combination (Abbott/
Murex, Wiesbaden, Germany) fourth-generation as the conﬁrma-
tory test. If there was a discrepancy between the Vironostika and
Murex tests, the samples were conﬁrmed by Enzygnost HIV
Integral II (Dade Behring, Marburg, Germany). All eligible women
were enrolled consecutively in the survey for 6 months from May
to November 2011.
Data on routine PMTCT HIV testing uptake and the surveillance
ELISA results from the NRL (considered the gold standard) were
used to calculate the following measures: (1) the uptake of routine
PMTCT HIV testing; (2) the agreement between routine PMTCT HIV
testing results and ANC-HSS testing results as measured by positive
and negative percentage agreement (PPA and NPA; the PPA was
calculated as the proportion of pregnant women found HIV-positive
by ANC-HSS who were identiﬁed as HIV-positive by rapid
diagnostic testing, while the NPA was the percentage of pregnant
women found HIV-negative by ANC-HSS who were identiﬁed as
HIV-negative by rapid diagnostic testing); (3) percentage bias,
which was the percentage difference from the HIV prevalence
among all women enrolled in the antenatal clinic and the HIV
prevalence among women who accepted PMTCT HIV testing.
2.2. PMTCT HIV testing quality assurance assessment
A WHO standardized checklist was used to assess all areas of
PMTCT HIV rapid testing quality assurance.3 Data were collected in
April and May 2013. The checklist was administered to all sentinel
sites by a surveillance staff member with laboratory training. The
checklist recorded the presence of quality assurance elements in
PMTCT HIV testing in three phase categories: pre-testing phase,
testing phase, and post-testing phase. Every quality assurance
element in the checklist that met the deﬁned standard was scored
1 point. The sentinel site was considered to be within acceptable
quality assurance parameters if the assessment score was at least
80% in each of the three phase categories. The score was produced
by calculating the percentage of possible points that were awarded.
2.3. PMTCT data quality assessment
A data quality assessment of PMTCT routine data was
conducted through an adapted WHO standard checklist.3 The
quality of surveillance variables of interest in routine ANC registers
was assessed retrospectively for women meeting the eligibility
criteria of the 2011 ANC-HSS (pregnant women making their ﬁrst
ANC visit during their current pregnancy) during the period
September 2012 to February 2013. Fifteen key variables were
assessed: ANC code, PMTCT code, age, visit date, gravidity, parity,
marital status, residence, occupation, education, HIV testing date,
HIV test result, syphilis screening date, syphilis screening results,
and previous HIV testing. The variables were assessed for
completeness and validity. A ﬁeld was considered complete if
there was a value present and valid if the recorded value was in the
expected range.3 The proportion of records with complete and
valid data was reported for each variable. Site was treated as a
clustering variable to allow for intra-site correlations when
calculating the conﬁdence intervals around the estimates.
2.4. Ethical considerations
For the comparison of PMTCT HIV results and the 2011 ANC-
HSS results, a linked conﬁdential testing procedure with informed
consent approach was used. Participants gave informed consent to
Table 1
Agreement between antenatal care surveillance-based ELISA test results and PMTCT-based routine rapid test results, Rwanda 2011
ELISA-
positive
ELISA-
negative
ELISA HIV
prevalence
estimate
PMTCT HIV
prevalence
estimate
PPAa NPAb
PMTCT-
positive (n)
PMTCT-
negative (n)
PMTCT-
positive (n)
PMTCT-
negative (n)
Overall (n = 13 279) 432 10 10 12827 3.3
(2.6–4.0)
3.3
(3.0–3.6)
97.51
(95.65–99.38)
99.85
(99.74–99.96)
Rural
(n = 6626)
118 1 5 6502 1.8
(1.4–2.2)
1.8
(1.5–2.2)
98.32
(96.26–100.00)
99.82
(99.62–100.00)
Urban
(n = 6653)
314 9 5 6325 4.8
(4.1–5.6)
4.9
(4.3–5.3)
97.21
(94.54–99.88)
99.89
(99.77–100.00)
PMTCT, prevention of mother-to-child transmission.
a The positive percentage agreement (PPA) was calculated as the proportion of pregnant women tested HIV-positive by ELISA who were identiﬁed as HIV-positive by rapid
testing
b The negative percentage agreement (NPA) was calculated as the percentage of pregnant women tested HIV-negative by ELISA who were identiﬁed as HIV-negative by
rapid testing.
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post-test counseling of routine PMTCT HIV testing. Blood speci-
mens were coded with a survey code and linked to the ANC code
that was considered as a personal identiﬁer. Using this link,
surveillance laboratory results were returned to sites and provided
to patients. Interview-based data collection was only performed
with eligible participants who provided informed consent.
Participant conﬁdentiality was ensured during the surveillance
activity. Participant names were not collected. All paper data were
maintained in lock-protected storage locations. Electronic data
were maintained on a single password-protected database. Once
all the surveillance laboratory results had been returned to sites/
patients, the ANC code was delinked from the surveillance
database before analysis.Table 2
Agreement between ANC HIV surveillance (ELISA) and PMTCT HIV testing (rapid
diagnostic test) results by site
Name of site Number PPA NPA
Bungwe 542 100 (80.5–100) 100 (99.3–100)
Busasamana 486 100 (63.1–100) 100 (99.2–100)
Byumba 492 100 (81.5–100) 100 (99.2–100)
CMS Bilyogo 447 100 (89.1–100) 100 (99.1–100)
CMS Gikondo 434 100 (90.0–100) 100 (99.1–100)
Gisenyia 416 90.9 (76.2–99.9) 99.7 (98.2–99.9)
Gitarama 476 96.0 (79.7–99.9) 100 (99.2–100)
Gitare 456 100 (47.8–100) 100 (99.2–100)
Kabuga 508 100 (87.2–100.0) 100 (99.2–100)
Kigembe 383 100 (29.2–100) 100 (99.0–100)
Kirehe 411 100 (54.1–100) 100 (99.1–100)
Mashesha 510 100 (54.1–100) 100 (99.3–100)
Mugina 370 100 (54.1–100) 99.5 (98.0–99.9)
Mukungu 383 100 (54.1–100) 100 (54.7–100)
Murunda 383 100 (69.2–100) 99.7 (98.5–100)
Musebeya 387 100 (29.2–100) 100 (99.0–100)
Nyagatarea 482 83.33 (58.6–96.4) 99.6 (98.5–99.9)
Nyamagabe 416 100 (78.2–100) 99.8 (98.6–100)
Nyanza 458 100 (81.5–100) 100 (99.7–100)
Rubengera 562 100 (87.2–100) 100 (99.3–100)
Ruhangoa 577 91.7 (73.0–99.0) 100 (99.3–100)
Ruhengeri 565 100 (86.8–100) 100 (99.3–100)
Ruhuha 340 100 (63.1–100) 99.7 (98.3–100)
Rukara 419 100 (59.0–100) 100 (99.1–100)
Rukomo 311 100 (59.0–100) 100 (98.8–100)
Ruli 388 100 (63.1–100) 100 (99.0–100)
Runyombyi 402 100 (39.8–100) 100 (99.1–100)
Rusizi 401 100 (84.6–100) 99.7 (98.5–100)
Rwamagana 426 100 (75.3–100) 99.8 (98.7–100)
Simbia 461 93.33 (68.1–99.8) 99.9 (98.8–100)
ANC, antenatal care; PMTCT, prevention of mother-to-child transmission; PPA,
positive percentage agreement; NPA, negative percentage agreement.
a Poor performing site: a site were PPA or NPA is <95%.3. Results
3.1. Capture of routine PMTCT HIV testing information as part of the
2011 ANC-HSS
With regard to the uptake of HIV testing in antenatal clinics
and potential biases, of the 30 ANC-SS sites that took part in the
PMTCT HIV testing assessment conducted from May to Novem-
ber 2011, 100% had provided PMTCT services since 2005. All of
the 13 292 eligible women consented to participate in the
2011 ANC-HSS, and 100% of these women, including those
known to be HIV-positive (n = 297), consented to routine PMTCT
HIV testing.
With regard to the comparison of PMTCT HIV testing and ANC-
HSS results, out of 13 292 women, 13 279 had both PMTCT HIV
rapid diagnostic test (RDT) and ANC-HSS ELISA test results. Of the
13 292, 442 (3.3%) tested positive by RDT. The overall HIV
prevalence according to both PMTCT using RDT and ANC-HSS using
ELISA testing was 3.3% (95% conﬁdence interval (CI) 3.0–3.7%)
(Table 1).
Individual-level comparison of PMTCT and surveillance HIV test
results revealed a PPA of 97.5% (95% CI 95.7–99.4%) and an NPA of
99.9% (95% CI 99.7–100.0%) (Table 1). The PPA and NPA were found
to be similar among urban and rural sites. Of the 30 sentinel sites,
19 (63.3%) had a PPA of 100% and an NPA of 100%. Four sites
showed a PPA of <95% and two had an NPA 99.7% (Table 2).
3.2. PMTCT HIV testing quality assurance assessment
The results of the assessment of PMTCT HIV rapid testing
quality assurance showed that laboratory registers were available
and accessible at all sites and were securely stored when not in use.
At all sites, routine HIV testing guidelines were available and the
national standardized algorithm with approved test kits was being
used. Although there is no printed laboratory register, all sentinel
sites had developed standardized handwritten laboratory HIV
rapid testing registers, which contained all the NRL recommended
information items. A checklist on PMTCT HIV rapid testing quality
assurance was used to collect information on the three deﬁned
phases of HIV testing quality assurance. The following HIV testing
quality assurance elements were most often missed and were
similar across the majority of sites: (1) pre-test phase: signed
records of all HIV rapid testing procedures (18.5%); (2) testing
phase: labeling test kits with date received, date opened, and
initials (29.6%); recording the kit names, lot numbers, and
expiration dates (29.6%). Findings indicated that 25 out of the
27 sentinel sites had a pass score (80%) in all three testing phases
(Table 3).
Table 3
HIV rapid testing quality assurance score at 27 antenatal sentinel surveillance sites
in Rwanda, 2012–2013
Sentinel sites Pre-test phase Testing phase Post-test phase
(n = 11 quality
elements)
(n = 15 quality
elements)
(n = 10 quality
elements)
Bilyogo 90.9 86.7 90.0
Bungwe 81.8 86.7 90.0
Busasamana 90.9 86.7 90.0
Byumba 81.8 86.7 90.0
Gikondo 90.9 93.3 90.0
Gisenyi 72.7 66.7 80.0
Gitarama 81.8 86.7 90.0
Gitare 81.8 93.3 90.0
Kabuga 81.8 86.7 90.0
Kigembe 90.9 93.3 80.0
Kirehe 81.8 86.7 90.0
Mashesha 81.8 86.7 90.0
Mugina 81.8 80.0 80.0
Murunda 81.8 80.0 80.0
Musebeya 81.8 93.3 80.0
Nyagatare 81.8 73.3 80.0
Nyamagabe 81.8 93.3 80.0
Nyanza 90.9 93.3 100.0
Rubengera 81.8 80.0 80.0
Ruhango 81.8 80.0 90.0
Ruhengeri 81.8 86.7 80.0
Ruhuha 90.9 93.3 90.0
Rukara 100 93.3 90.0
Rukomo 81.8 80.0 90.0
Rusizi 81.8 80.0 80.0
Rwamagana 81.8 86.7 90.0
Simbi 81.8 80.0 90.0
Table 4
Completeness and validity of HIV surveillance variables at 27 antenatal care
sentinel sites in Rwanda, 2012–2013a
Variable of interest Proportion of
completeness
(95% CI)
Proportion of
validity
(95% CI)
N = 19 389
ANC or PMTCT code 100 100
Date of visit 100 100.0 (99.9–100.0)
Age 99.0 (98.9–99.1) 100
Gravidity 94.0 (92.4–95.6) 100
Parity 96.0 (94.2–97.8) 99.6 (98.8–100.0)
Marital status 98.0 (97.2–98.8) 100 (99.9–100.0)
Residence 99.0 (98.5–99.5) 100 (99.9–100.0)
Educationb - -
Occupationb - -
HIV test date 100 100
HIV test result 100 100
Syphilis test offered date 50.0 (43.2–56.8) 100 (99.9–100.0)
Syphilis test result 49.0 (42.3–55.7) 100 (99.9–100.0)
Previously known HIV status 92.0 (84.0–100.0 94.6 (86.0–103.1)
Partner visited ANC services 99.0 (98.8–99.2) 100
Partner HIV test result 98.0 (97.6–98.4) 100
Partner shared HIV test results 97.0 (96.7–97.3) 100
CI, conﬁdence interval; ANC, antenatal care; PMTCT, prevention of mother-to-child
transmission.
a Site was treated as a clustering variable to allow for intra-site correlations when
calculating the conﬁdence intervals.
b Education and occupation are among the World Health Organization variables
of interest for the assessment of readiness of PMTCT routine data for HIV sero-
surveillance; however these data were not routinely recorded in the ANC register in
Rwanda.
H. Balisanga et al. / International Journal of Infectious Diseases 52 (2016) 62–67 653.3. PMTCT data quality assessment
Records of 19 389 eligible women attending ANC services at
27 sites during September 2012 to February 2013 were assessed.
Results showed that the routine recording of 13 variables (ANC
number, PMTCT code, date of visit, age, parity, gravidity, marital
status, residence, HIV and syphilis testing date, HIV and syphilis
results, and previously known HIV status) was standardized in the
ANC/PMTCT register in a standardized fashion at the ﬁrst ANC visit.
Education and occupation were not routinely captured. In addition,
routine recording of six variables (ANC code, age of client, date of
HIV and syphilis test, and corresponding results) were done in the
handwritten laboratory registers (Table 4).
Key variables of interest assessed showed levels of complete-
ness and validity above 90% in the ANC/PMTCT register. For the 19
389 women recorded in ANC/PMTCT registers, the ANC code, visit
date, HIV testing date, and HIV testing results were complete and
valid for 100%. Ninety-nine percent of women recorded had age
and residence complete and valid. Syphilis screening date and
testing results were only complete for respectively 50% and 49% of
records (Table 4).
4. Discussion
As international guidelines recommend a shift from ANC-HSS to
using routine PMTCT-SS, it was found that Rwanda is ready to
make this transition. The assessment was comprehensive, follow-
ing WHO recommendations, and assessed several elements of the
PMTCT program and routine data. The ﬁndings show a very high
uptake of routine HIV testing among ANC attendees at sentinel
sites. The core surveillance variables of interest from the PMTCT
data quality assessment were routinely recorded in an ANC/PMCT
standardized register, with a high degree of completeness and
validity. There were robust quality assurance measures for routine
PMTCT HIV testing, and a high level of agreement between routine
PMTCT HIV rapid testing and surveillance ELISA HIV testing.Several countries have completed similar exercises to determine
their readiness, but results have varied for HIV testing uptake, data
quality, or concordance between test results.4,6–8,10–18
The readiness to transition to PMTCT-based surveillance is due
to several marked successes of the Rwandan HIV program, ﬁrst and
notably the integration and universal coverage of ANC/PMTCT
services. The Government has rapidly scaled up PMTCT programs
over the years, with coverage doubling between 2005 and
2011. Among the sentinel sites, the high uptake of HIV testing
at ANC/PMTCT services is due to the strong response to the HIV
epidemic in Rwanda and the greater awareness of the importance
of PMTCT services fully integrated within ANC services.19 These
data corroborate other ﬁndings from the Rwandan National HIV
Program, which have indicated that the uptake of HIV testing
among ANC attendees nationally increased from 34.4% in 2005 to
100% in 2007 and 98.4% in 2012.6 Similar increases have been
observed in Kenya, where the coverage of PMTCT services
increased from 15% in 2003 to 100% in 2005, and the uptake of
HIV testing from 56% in 2003 to 99% in 2010.10,20 From these data,
it seems that earlier identiﬁed barriers to the uptake of testing in
the ANC programs of other countries (including perception of
higher risk of infection, unwillingness to test without a partner’s
consent, educational level, age, parity, gravidity, employment,
marital status, partner’s occupation, and residence)5,21,22 did not
affect the uptake of HIV testing in Rwanda. This universal
acceptance of routine PMTCT HIV testing among study participants
in Rwanda removed the non-consent bias inherent in PMTCT
program data. Additionally, to minimize a potential systematic
source of selection bias, pregnant women who already knew their
HIV status to be positive at ﬁrst ANC visit were also solicited and
accepted to PMTCT HIV testing.
The high completeness and validity of surveillance variables in
routine PMTCT registers may be attributed to the recent activities
to improve site data quality, such as site supervision and
mentorship visits, integrated training, and experience of staff.
The quality was markedly better than the results from a
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surveillance variables spread across several logbooks.10 However,
the present assessment found that syphilis screening and syphilis
screening results – one of the main ANC-HSS variables of interest23
– had low levels of completeness, possibly due to the frequent lack
of available rapid plasma reagin (RPR) reagents. This low syphilis
completeness may have implications for the WHO recommenda-
tions to combine HIV, syphilis, and viral hepatitis screening in
pregnant women attending ANC, because inconsistent syphilis
testing constitutes an obstacle to the effective integrated ANC
services.24–26 WHO recommendations would be achievable if
testing services resources were integrated and reagents appropri-
ately supplied.
A high level of positive and negative percentage agreement
between PMTCT RDT and surveillance HIV ELISA test results was
found. These results were corroborated by the robust PMTCT HIV
rapid testing quality assurance practices at most ANC sentinel sites
and may be attributable to the quality improvement strategies,
including services decentralization, integrated supervision, train-
ing and mentorship, and performance-based ﬁnancing. Despite
this, there were a few sites like Gisenyi, Nyagatare, Ruhango, and
Simbi that demonstrated lower performance, possibly due to
trained personnel turnover, overly high staff workloads, or
inadequate laboratory practices. These factors should be studied
in the future.
Very few studies have examined individual-level agreement
between PMTCT and surveillance HIV test results, notably a study
from Mozambique that found a PPA of only 88.5%.21 Most
published studies have been limited to comparing PMTCT and
ANC surveillance HIV test results through prevalence. Studies
conducted in Sub-Saharan Africa found similar prevalence when
ANC surveillance and PMTCT data were compared across
participating clinics.8,10,14,27 However, in a 2005 Uganda study, a
higher HIV prevalence was observed among women who accepted
voluntary counseling and testing as compared to those who tested
anonymously.28 In Kenya the UAT and PMTCT data were compared
at the same clinics and for the same time period. The HIV testing
uptake for PMTCT was deﬁned as the number of ANC attendees
tested for HIV out of those who had their ﬁrst ANC visit during the
ANC surveillance period. It showed that there was considerable
inter-clinic variability of HIV prevalence estimates at the same
clinics and for the same time period.10
Although the NPA is quite high, in a country with a low
prevalence like Rwanda, where most women are negative, even
this high NPA, when applied to the large number of negative
women, will translate into an insigniﬁcant number of HIV-negative
women receiving false-positive HIV testing results. This scenario
could lead to treating uninfected persons for HIV. Sub-100% PPA
and NPA reinforce the need for quality assurance of HIV testing and
counseling.29
There are several limitations to this study that should be
considered. First, the comparison of individual HIV RDT and ELISA
results may be affected by differences in staff performance and
technology capacity. This is likely minor because there have been
no changes to the national HIV testing algorithm. Three sites out of
30 were not assessed because the assessment was conducted
during the rainy season and the sites were not accessible. However,
researchers believe that the general ﬁndings would apply to these
three sites because every site in Rwanda applies the same
standards. Finally, it is important to note that these ﬁndings
apply directly to the Rwanda program and should not be
generalized to other countries. While each country will have to
assess their own readiness to transition to PMTCT-based sero-
surveillance, this study is useful outside of Rwanda as it
demonstrates how to apply the WHO guidelines appropriately
for this assessment.In conclusion, Rwanda is ready to switch from ANC to PMTCT
sero-surveillance; the country meets the WHO standards regard-
ing universal acceptance of HIV testing, accuracy of diagnostic
testing, high data quality, and high coverage of HIV testing at the
health facility level. Additional efforts should be made to ensure
the sustainability of high quality data and to avoid running out of
consumables, as occurred in the case of syphilis reagents.
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